Recent Financings of Private Companies (10/2011)

01 Oct 2011

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.

Linkage Biosciences Inc. (developing tissue-typing molecular diagnostics) brought in $2.1mm via its Series B round led by Fisher Capital and Greenhouse Capital Partners. All other major returning investors, including Big Sky Partners, also participated. Funding will support scale-up manufacturing activities and regulatory approvals in the US and Europe for its LinkSeq tests. The company's Series A generated $2mm back in early 2009. (Sep.)

Metabolon Inc. (biochemical profiling tools for biomarker and pathway discovery mainly in oncology, but also in insulin resistance, ALS, and vitamin D deficiency) has completed a $13.2mm Series D...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

16 Sep 2024

• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

04 Sep 2024

• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

23 Aug 2024

• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

29 Jul 2024

• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand